Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04343365

Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Incurable Disease

Sex eligibility

All sexes

Study type

Observational

Primary location

Moffitt Cancer Center

Tampa, Florida, 33613, United States

Location status: Recruiting

Location contact

Alexander Anderson, PhD

SUB_INVESTIGATOR

Christine Chung, MD

SUB_INVESTIGATOR

Jingsong Zhang, MD

PRINCIPAL_INVESTIGATOR

Joel Brown, PhD

SUB_INVESTIGATOR

Michael Schell, PhD

SUB_INVESTIGATOR

Sara Donadelli

CONTACT

[email protected]

813-745-8111

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
  • Participant must have a life expectancy greater than 3 months
  • Participant must have an ECOG performance status 0-2
  • Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
  • Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.

Exclusion criteria

  • None

Treatment and study plan

Evolutionary Tumor Board (ETB)

Other

The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation

Primary outcomes

  1. ETB developing therapeutic strategies

    Time frame: Baseline to up to 60 months from end of therapy

    The investigators want to demonstrate the ability of a multidisciplinary group, the ETB, to develop therapeutic strategies in participants without curative options. They plan to enroll 35 patients to this study over 3 years. The primary objective will be successfully met if they can develop an evolutionary based plan that differs from the participants options prior to presentation for at least 80%, or 28 of these participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Sara Donadelli

CONTACT

[email protected]

813-745-8111

Sponsors and collaborators

Lead sponsor

H. Lee Moffitt Cancer Center and Research Institute

Other

Registry information

Official study title

Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients

Important dates

Study start
2020
Primary completion
2028
Study completion
2028
First posted
Apr 13, 2020
Registry last updated
Apr 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.